SSI Diagnostica Group continues to strengthen the leadership team with the appointment of Finn Albrechtsen as the new Head of Global R&D. Finn has most recently held the CEO position at Vidya Ltd. (VC) as well as VP for R&D and Business Development at Thermo Fisher Scientific Microbiology Division. Prior to that Finn was Snr. Director at Agilent and the Diagnostics & Genomics Portfolio and Project Management Office (PMO). His combined experience within strategy execution, change management across product pipeline is a strong match to the SSID Group.

The fundamental DNA of our company is built on our specialization within Clinical Diagnostics & Surveillance of Infectious Disease for more than 100 years. As a trusted partner to the science community, Finn’s extensive experience within Microbiology and Clinical Diagnostics will help us prioritize and accelerate our R&D pipeline across the Group entities, says the Group CEO Christina Lindved.

The SSID Group has been owned By Adelis Equity Partners since 2016 and in May 2023 a new Chairman and Board of Directors was announced to strengthen the continuous growth journey.

Christina Lindved

CEO, SSI Diagnostica Group